The main limitation of drug-eluting stents (DES) is the occurrence of delayed restenosis, which is decisively caused by the polymer. Polymer-free stents however, proved not to be superior. Hence by adding estradiol to a rapamycin-eluting stent, it was tried to improve the efficiacy of the stent. Advantages of estradiol are its lipophilic character, which slows down the elusion of the drug, and secondly the promotion of the reendothelialization after stent implantation. In a clinical trial, however, this hypothesis could not be confirmed.
«
The main limitation of drug-eluting stents (DES) is the occurrence of delayed restenosis, which is decisively caused by the polymer. Polymer-free stents however, proved not to be superior. Hence by adding estradiol to a rapamycin-eluting stent, it was tried to improve the efficiacy of the stent. Advantages of estradiol are its lipophilic character, which slows down the elusion of the drug, and secondly the promotion of the reendothelialization after stent implantation. In a clinical trial, howev...
»